Have a personal or library account? Click to login
SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study Cover

SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study

Open Access
|Nov 2024

Abstract

SARS-CoV-2 infection often causes neurological disorders. Experimental studies on an animal model have shown that SARS-CoV-2 is able to cross the blood-brain barrier. Researchers have also discovered that SARS-CoV-2 can infect glial cells. Gliomas are the most common type of brain tumor. Oncological patients are at high risk of infections, including SARS-CoV-2. Moreover, their weakened immunity causes the level of antibodies after infection or vaccination to be lower than in the healthy population. Therefore, the aim of our study was to evaluate the occurrence of SARS-CoV-2 RNA in tumor tissue collected during surgery. We also tested the level of anti-SARS-CoV-2 antibodies in these patients. The obtained results indicate the tropism of the virus to tumor tissue – glioblastoma. The level of anti-SARS antibodies was higher in patients with SARS-CoV-2 RNA detected in tumour tissue.

DOI: https://doi.org/10.2478/cipms-2024-0035 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X
Language: English
Page range: 216 - 220
Submitted on: Feb 10, 2024
|
Accepted on: Oct 20, 2024
|
Published on: Nov 28, 2024
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Michal Brzozowski, Marcin Kolesnik, Aleksander Michalski, Katarzyna Drop, Malgorzata Polz-Dacewicz, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.